17996-12-2

Basic information

• Product Name: 6-(Z-AMINO)-1-HEXANOL
• Synonyms: 6-(Z-AMINO)-1-HEXANOL;CBZ-6-AMINO-HEXAN-1-OL;BENZYL N-(6-HYDROXYHEXYL)CARBAMATE;Z-NH-(CH2)6-OH;Z-ACP(6)-OL;N-CARBOBENZOXY-6-AMINO-1-HEXANOL;N-CARBOBENZOXY-DELTA-AMINOHEXYL ALCOHOL;Carbamic acid, (6-hydroxyhexyl)-, phenylmethyl ester
• CAS NO: 17996-12-2
• Molecular Formula: C₁₄H₂₁NO₃
• Molecular Weight: 251.32
• Mol File: 17996-12-2.mol
• Article Data: 39

Chemical Properties

• Melting Point: 80-82 °C
• Boiling Point: 419.6°C at 760 mmHg
• Flash Point: 207.6°C
• Appearance: /
• Density: 1.087g/cm³
• Vapor Pressure: 8.59E-08mmHg at 25°C
• Refractive Index: 1.522
• Storage Temp.: Sealed in dry,Room Temperature
• BRN: 2121987
• CAS DataBase Reference: 6-(Z-AMINO)-1-HEXANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(Z-AMINO)-1-HEXANOL(17996-12-2)
• EPA Substance Registry System: 6-(Z-AMINO)-1-HEXANOL(17996-12-2)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 17996-12-2(Hazardous Substances Data)

Usage

General Description

6-(Z-AMINO)-1-HEXANOL is a chemical compound with the molecular formula C7H16NO and a molecular weight of 128.20 g/mol. It is an amino alcohol that consists of a hexane chain with an amino group and a hydroxyl group attached to it. The Z-configuration indicates that the amino group is on the same side as the longest continuous carbon chain in the compound. 6-(Z-AMINO)-1-HEXANOL is commonly used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. It also has potential applications in the field of organic chemistry and biochemistry due to its versatile reactivity and functional groups.

InChI:InChI=1/C14H21NO3/c16-11-7-2-1-6-10-15-14(17)18-12-13-8-4-3-5-9-13/h3-5,8-9,16H,1-2,6-7,10-12H2,(H,15,17)

Upstream product

• 4048-33-3 6-amino-1-hexanol 
• 501-53-1 benzyl chloroformate 
• 1885-14-9 phenyl chloroformate 
• 1189-71-5 isocyanate de chlorosulfonyle 
• 629-11-8 1,6-hexanediol 
• 100-51-6 benzyl alcohol 
• 1947-00-8 6-(benzyloxycarbonylamino)hexanoic acid 
• 60-32-2 6-aminohexanoic acid 
• 62252-26-0 JLK 6 
• 1308344-06-0 benzyl (6-((4-methoxybenzyl)oxy)hexyl)carbamate 
• 1258782-72-7 C₂₁H₂₅NO₄ 
• 1258782-57-8 C₁₆H₂₃NO₄ 
• 25580-87-4 methyl 6-(((benzyloxy)carbonyl)amino)hexanoate 
• 60-29-7 diethyl ether 

Downstream Products

• 62205-56-5 6-(N-benzyloxycarbonylamino)hexyl-O-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy)-β-D-glucopyranoside 
• 66888-24-2 6-(benzyloxycarbonylamino)hexyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside 
• 201737-04-4 6-benzyloxycarbonylaminohexyl β-D-galactopyranoside 
• 117703-07-8 6-(N-benzyloxycarbonylamino)-hexyl 2-O-<4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyrasonyl)-3,6-di-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl>-(3,4,6-tri-O-benzyl)-α-D-mannopyranoside 
• 117703-06-7 6-(N-benzyloxycarbonylamino)-hexyl-3,4,6-tri-O-benzyl-α-D-mannopyranoside 
• 117703-09-0 6-(N-benzyloxycarbonylamino)-hexyl 2-O-(4-O-β-D-galactopyranosyl-2-acetamido-2-deoxy-β-D-glucopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranoside 
• 117703-08-9 6-(N-benzyloxycarbonylamino)-hexyl 2-O-(4-β-D-galactopyrasonyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-3,4,6-tri-O-benzyl-α-D-mannopyranoside 
• 1236324-40-5 (3S)-4-[2-(6-benzyloxycarbonylaminohexyl)-2-tert-butoxycarbonylhydrazino]-3-tert-butoxycarbonylaminobutyric acid benzyl ester 
• 1611468-72-4 N-(benzyloxycarbonyl)-10-amino-5-decanol 
• 213194-02-6 6-Benzyloxycarbonylaminohexyl 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranoside 
• 189108-65-4 Acetic acid (2R,3R,4R,5R,6R)-2-acetoxymethyl-5-azido-6-(6-benzyloxycarbonylamino-hexyloxy)-4-((2R,3R,4S,5S,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yl ester 

Relevant articles and documents

ACRIDIN-9-YL-AMINE, QUINOLIN-9-YL-AMINE, 1 -AMINO-9H-THIOXANTHENE-9-ONE AND BENZO[B][1,5]NAPHTHYRI DIN-10-YL-AMINE DERIVATIVES AS AUTOPHAGY INHIBITORS FOR TREATING CANCER

This disclosure provides a cridin-9-yl-amine, quinolin-9-yl-amine, 1- amino-9H-thioxanthene-9-one and benzo[b][l,5]naphthyridin-10- yl-amine derivatives and structurally related compounds for use as autophagy inhibitors for treating cancer. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 77 to 155; examples 1 to 22; compound A; compounds 1 to 21; tables 1 to 3).

Synthetic method 6-amino-1-hexanol

The invention discloses a synthetic method 6-amino-1-hexanol. According to the synthetic method 6-amino-1-hexanol, chlorosulphonyl isocyanate and 1, 6-hexanediol are taken as main raw materials, one-pot method is adopted to synthesize 6-amino-1-hexanol. The synthesis route comprises following steps: 1, under the catalyst effect of a tertiary amine, chlorosulphonyl isocyanate and a primary alcoholare reacted to generate a Burgess reagent, 1, 6-hexanediol is added to generate an intermediate 6-hydroxyhexyl carbamic acid; and 2, the intermediate 6-hydroxyhexyl carbamic acid synthesized in step is subjected to projecting group removing directly without separation so as to obtain target product 6-amino-1-hexanol. The synthetic method is low in cost, simple in reaction conditions, few in reaction steps, short in time, and high in purity and yield of finished product 6-amino-1-hexanol.

Toward aplyronine payloads for antibody-drug conjugates: Total synthesis of aplyronines A and D

The aplyronines are a family of antimitotic marine macrolides that disrupt cytoskeletal dynamics by dual targeting of both actin and tubulin. Given their picomolar cytotoxicity profile and unprecedented mode of action, the aplyronines represent an excellent candidate as a novel payload for the development of next-generation antibody-drug conjugates (ADCs) for cancer chemotherapy. Enabled by an improved second-generation synthesis of the macrolactone core 5, we have achieved the first total synthesis of the most potent congener aplyronine D together with a highly stereocontrolled synthesis of aplyronine A. To facilitate step economy, an adventurous site-selective esterification of the C7 hydroxyl group was performed to install the N,N,O-trimethylserine pharmacophore to directly afford aplyronines A and D. Toward the assembly of ADCs incorporating an aplyronine warhead, the C29-ester derivative 4 featuring an Fmoc-amino substituted linker attached to the actin-binding tail region was also prepared by adapting this flexible endgame.